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HIVIn the CNS, microglia are the primary targets of HIV infection. In this study, we investigated the effect of
activation of the innate antiviral receptors TLR3 and TLR4 on HIV infection of primary human microglia, as
well as microglial cell signaling and gene expression. Ligands for both TLR3 and TLR4 potently inhibited HIV
replication in microglia through a pathway requiring IRF3. Surprisingly, a remarkably similar pattern of cell
signaling and gene expression was observed in TLR3- and TLR4-activated microglia, suggesting a relatively
minor role for MyD88 following TLR4 activation in these cells. HIV did not activate IRF3 but rather decreased
IRF3 protein, indicating that HIV does not activate TLR3 or RIG-like helicases in microglia. Taken together,
these results indicate that activation of TLR3 or TLR4 will elicit antiviral immunity, in addition to inducing
proinﬂammatory responses. We suggest that a balanced expression between inﬂammatory and innate
immune genes might be achieved by IRF3 over-expression.
© 2009 Elsevier Inc. All rights reserved.Introduction
Cells of the immune system bear toll-like receptors (TLRs) and
respond to TLR ligands by expressing a number of genes involved in
innate and adaptive immune responses against microbial infection.
The TLRs that recognize viral pathogen-associated molecular patterns
(PAMPs) are TLR3 (dsRNA), TLR7/8 (single stranded RNA) and TLR9
(DNA) (Akira et al., 2006; Kawai and Akira, 2007; O'Neill, 2008).
TLR3 can also be activated by synthetic dsRNA, poly-riboinosinic-
ribocytidylic acid (PIC). In addition to innate immunity, dsRNA could
also boost adaptive immunity against viral infection, for example, by
cross-priming viral-speciﬁc CD8+ CTLs (Seya et al., 2003, 2006; Salio
and Cerundolo, 2005). Indeed, TLR ligands are used as adjuvants for
the formation of an effective adaptive immune response.Whether HIV
can form viral PAMPs that activate TLRs in microglia is unknown, but
there is evidence that HIV can activate TLR7/8, and possibly TLR9, in
dendritic cells and macrophages (Beignon et al., 2005; Heil et al.,
2004). Of the CNS cells, both microglia and astrocytes of rat, mouse
and human origin have been extensively studied for TLR-mediated, double stranded RNA; eIF2α,
ogen synthase kinase 3β; IDO,
se ɛ; IRF, interferon regulatory
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l rights reserved.activation (Bsibsi et al., 2002; Carpentier et al., 2008; McKimmie and
Fazakerley, 2005). TLR3 is the predominant TLR on astrocytes that
mediates activation of antiviral, as well as inﬂammatory genes (Bsibsi
et al., 2006; Carpentier et al., 2005; Farina et al., 2005; Rivieccio et al.,
2005), and treatment of astrocytes with PIC elicits strong antiviral
activity against HIV and HCMV (Rivieccio et al., 2006; Suh et al., 2007).
Microglia express all known TLRs and respond robustly to both PIC
(TLR3 ligand) and LPS (TLR4 ligand) (Carpentier et al., 2008; Jack et
al., 2005; Town et al., 2006). Whether the activation of these immune
receptors in microglia results in suppression of intracellular viral
replication is unknown. The detailed intracellular signal activation
cascades as well as comprehensive gene expression studies have not
been performed, especially with respect to TLR3 activation.
Microglia are CNS immune cells that play a major role in the
antiviral response during microbial invasion and infection (Rivest,
2003; Dickson et al., 1991). Microglia also serve as the major targets of
infection by HIV in the CNS, and are the prime instigator of HIV-
associated neurocognitive disorders (HAND) including HIV-dementia
(HAD) (Dickson and Lee, 1996; Kaul et al., 2001; Gonzalez-Scarano
and Martin-Garcia, 2005; Persidsky and Gendelman, 2003). The
interactions between microglia and the HIV virion, HIV products, or
inﬂammatory mediators generated during infection, are thought to
lead to the cascades of events in the CNS that ultimately results in
neuronal damage (Ellis et al., 2007). The properties of microglia that
contribute to this neurodegenerative process in HAND, as well as
several other chronic neurodegenerative disorders, include the
presence of cell surface receptors that render them highly reactive
to a variety of innate and adaptive immunological stimuli (Kreutzberg,
1996; Perry and Gordon, 1988; Streit et al., 2005). For example,
microglia are exquisitely sensitive to the TLR4 ligand, LPS, and are
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(Laﬂamme and Rivest, 2001). LPS is a potent activator ofmicroglia that
induces proinﬂammatory cytokines and reactive oxygen radicals that
have been shown to cause death of neurons and oligodendrocytes in a
number of experimental systems (Chao et al., 1992; Cai et al., 2003;
Lehnardt et al., 2002). However, microglial activation does not always
lead to neurodegeneration, as microglia can also generate growth
factors (including brain-derived neurotrophic factors and insulin-like
growth factors) and anti-inﬂammatory cytokines that can contribute
to neuroprotection (Gordon, 2003; Hanisch and Kettenmann, 2007;
Schwartz et al., 2006). In addition, there is evidence that proinﬂam-
matory cytokines and LPS can elicit an antiviral program in microglia
(Lokensgard et al., 1997; Si et al., 2004 and unpublished). Currently,
the heterogeneity of microglia with respect to their activation pheno-
types and their role in disease progression and repair is an area of
active investigation.
Investigating microglial TLRs is particularly relevant to HIV
diseases. For example, recent studies have demonstrated signiﬁcant
levels of plasma LPS that exist in HIV+ individuals (Brenchley et al.,
2006), which might be a signiﬁcant modiﬁer of the HIV diseases.
Speciﬁcally, Ancuta et al. (2008), have reported that the levels of
plasma LPS correlate with the degree of monocyte activation and the
presence of HAD in patients with AIDS. LPS has been found to
promote glial cell activation and HIV expression in a HIV-transgenic
mouse model (Sun et al., 2008). LPS has also been found to promote
transmigration of HIV+ monocytes into the brain (Wang et al.,
2008). These ﬁndings together suggest that HIV-infected individuals
are at risk for “activating” peripheral and brain macrophages through
TLR4.
In the current study, we investigated the role of TLR3 in microglial
activation with respect to its intracellular signal activation, gene
induction and antiviral activity, using HIV as a target virus. Since TLR4
is the only other member of the TLR family that can also activate
human IFNβ gene expression through activation of IRF3 (Hiscott et al.,
2006), we compared microglial responses to TLR3 activation with
TLR4 activation. To determine if HIV infection activates IRF3, we also
examined HIV-infected microglial responses. The results demon-
strated that while there was no signiﬁcant degree of IRF3 activation in
HIV-infected microglia, HIV infection causes a decrease in the amount
of IRF3. On the other hand, triggering TLR3 or TLR4 by PIC or LPS
induced strong anti-HIV activity in microglia. Remarkably, TLR3 and
TLR4 activation induced the same intracellular cell activation path-
ways and induced essentially the same sets of genes in microglia,
including proinﬂammatory cytokines, chemokines and IFN-stimu-
lated genes (ISGs). Among the minor differences noted were slightly
higher induction of many ISGs by PIC compared to LPS, and slightly
higher induction of many non-IRF3-dependent genes by LPS relative
to PIC. These results together demonstrate that TLR3 and TLR4 are the
major innate antiviral immune receptors in microglia but that
inappropriate activation of these TLRs could also result in a pathogenic
outcome through induction of the chronic inﬂammatory state. Since
TLR ligands are being actively considered for antiviral and adjuvant
therapy, the latter will be an important issue to address in the context
of the CNS environment.
Results
TLR3 and TLR4 activation suppresses HIV in microglia (Figs. 1A and B)
We examined the role of TLR3 and TLR4 ligands in modulation of
HIV expression in microglia. Primary human fetal microglia were
treated or not with PIC (10 μg/ml) and immediately infected with the
R5 strain of HIV (BaL) (Fig. 1A). HIV gag in culture supernatants was
measured by ELISA and the cells were also immunostained for HIV
gag. PIC nearly completely inhibited HIV gag expression in microglia.
Since it takes 1–3 weeks for productive infection to occur in thespreading infectionmodel (Lee et al., 1993; Si et al., 2004), we adopted
VSVg env HIV (NL4.3, Nef-intact, Vpr-intact) for synchronized single-
cycle infection of microglia, in which HIV gag becomes detectable
within 1–2 days (Fig. 1B). Using VSVg env HIV, we were able to
demonstrate anti-HIV activity of PIC in more than 20 independent
experiments. The suppression ranged from near complete to partial
when PIC was co-administered with HIV, with pretreatment resulting
in stronger suppression (not shown). For example, by cell-based ELISA
assay for HIV gag, we observed 45%, 57%, 63%, 92% and 96% of HIV
inhibition on day 4 in PIC-co-treated microglial cultures compared to
cultures exposed to HIV alone. Unexpectedly, the TLR4 ligand LPS also
suppressed HIV in microglia (Fig. 1B). The degree of inhibition also
ranged from complete to partial (∼60%).
Effect of TLR3 or TLR4 activation on HIV expression in U1 cells (Fig. 1C)
TLRs activate the antiviral pathway in host cells by inducing ISGs
(Sen and Peters, 2007), many of which act by suppressing viral gene
transcription or translation. We therefore tested whether PIC or LPS
could suppress HIV expression in U1 cells, a humanmonocytic cell line
with stably integrated copies of HIV provirus, thus a post-integration
latency model. U1 cells were treated with PIC, LPS or IL-1β, indi-
vidually or in combination, and Western blot was performed to mea-
sure HIV gag expression. The results showed that while PIC alone
induced negligible amounts of HIV gag, LPS and IL-1β induced higher
amounts of HIV expression and PIC did not suppress LPS- or IL-1β-
induced HIV expression in U1 cells (Fig. 1C). Furthermore, PIC at times
slightly enhanced HIV expression induced by LPS or IL-1β (Fig. 1C and
data not shown). These results show that effects of the TLR ligands and
IL-1 on HIV expression are different depending on the HIV infection
model used.
TLR9 ligand CpG ODN also suppresses HIV (Fig. 1D)
In addition to TLR3 and TLR4, we also tested the role of the TLR9
ligand CpG ODN in microglial HIV expression and found it to be
suppressive. However, the control GpC ODN also suppressed HIV ex-
pression in microglia, suggesting that the antiviral effect of CpG ODN
was mediated by phosphorothioate modiﬁcation rather than through
activating TLR9.
TLR3 and TLR4 ligands activate IRF3 in microglia (Fig. 2A)
Ligand binding to TLR3 or TLR4 recruits the TIR-domain-contain-
ing adaptor TRIF which then phosphorylates IRF3 through the
activation of recently identiﬁed IRF3 kinases, TBK1 and IKKɛ (also
called IKKi) (Sharma et al., 2003; Fitzgerald et al., 2003). The recruit-
ment of TRIF to TLR3 or TLR4 also activates the canonical IKKs (α, β
and γ), which then activate NF-κB and MAP kinases. NF-κB, MAP
kinases and IRF3 are all required to activate human IFNβ gene
(primary response gene) (Enoch et al., 1986; Lenardo et al., 1989).
Secreted IFNβ then activates the Jak/Stat pathway in an autocrine
manner resulting in the transcriptional induction of ISGs (secondary
response genes).
Given the similar anti-HIV activity shown by PIC and LPS in
microglia, we sought to systematically examine the activation of
intracellular signaling pathways in microglia treated with PIC or LPS.
We ﬁrst examined nuclear translocation of IRF3 by determining the
amounts of IRF3 protein in nuclear extracts. Fig. 2A shows that in PIC-
treated microglia, IRF3 is translocated to the nucleus as early as
20 min, and persisted through 24 h. In LPS-treated cells, IRF3
translocation was noticeable at 1 h, then was suppressed. pY-Stat1
(marker of IFN production) was detected at 6 h post-stimulation in
both, with PIC inducing a higher level than LPS. These results show
that both PIC and LPS activate IRF3 leading to IFNβ production in
microglia.
Fig. 1. Anti-HIV activity of microglia activated by TLR3 and TLR4 ligands: (A) PIC effectively suppresses spreading HIV infection in primary human microglia. Microglia in 96 well
plates in four replicates were exposed to HIVBaL±PIC (10 μg/ml) in DMEM 5%FCS, as described in Materials and methods. Cultures were examined 16 days after infection by
immunocytochemistry for HIV p24 with nitroblue tetrazolium (blue) as chromogen. While HIVp24+microglia were numerous (BaL), they were not detected in PIC-treated cultures
(PIC). The same cell culture supernatants were examined for HIV p24 by ELISA and showed complete suppression of HIV production by PIC (panel to the right). (B) PIC and LPS
suppress replication of VSVg env HIV in microglia: to synchronize the intracellular HIV life cycle, microglia were infected with high concentrations of single-cycle, env-pseudotyped
HIV (pNL4-3) with or without PIC (10 μg/ml) or LPS (10 ng/ml), and viral production was examined 3 days later by HIV p24 immunocytochemistry. As shown, HIV p24+ cells were
dramatically reduced by PIC or LPS treatment (⁎⁎⁎pb0.001). (C) Effect of TLR3 or TLR4 activation on HIV expression in U1 cells: U1 cells were stimulated for 2 days with PIC, LPS, IL-1β
(10 ng/ml) or PMA (10 nM) alone or in combinations as shown. Western blot analysis was performed for HIV p24 expression, with vinculin as a loading control. While PIC induced
little or no HIV p24, LPS and IL-1β induced high levels of HIV p24. Also, PIC did not suppress LPS or IL-1-induced HIV expression but rather increased it. PMA was used as a positive
control for HIV induction in U1 cells. (D) The effect of the TLR9 ligand CpG ODN onmicroglial HIV expression: microglia were pretreated for 1 h with 5 μM of CpG ODN (TLR9 ligand)
or the control GpC ODN (both with phosphorothioate modiﬁcation to increase half-life), and then infected with VSVg env HIV for addition 50 h. HIV gag expressionwas examined by
Western blot analysis. HIV expression was inhibited not only by the TLR9 ligand CpG ODN, but also by control GpC ODN. In contrast, viperin induction by HIV was not inhibited by
either ODN. These results were repeatedwith cell-based ELISA (panel to the right) inwhich p24-immunostained, nitroblue-tetrazolium-positivemicroglia in 96well plates were read
using an ELISA reader at OD595. Results from triplicate wells are shown (⁎⁎pb0.01).
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and the induction of transcriptional factors and antiviral proteins
(Figs. 2B–D)
Additional intracellular signaling pathways were activated by PIC
and LPS in microglia. MAP kinase activation was examined in the
whole cell lysates: JNK, Erk and p38 MAPK were all phosphorylated
within 10 min of stimulation with PIC (Fig. 2B), similar to LPS (Kim et
al., 2002) (also see Fig. 2C). pS-Stat1 was induced within 20 min by
PIC, LPS and IFNβ, but not by IFNγ. Serine phosphorylation of Stat1 is
required for full transcriptional activation of Stat1, in addition to
pY-Stat1. IFNβ activation of p-Erk and pS-Stat1 in microglia is con-
sistent with previous data (Kim et al., 2002). p-Akt (downstream ofPI3K) was upregulated at 1 h after PIC- or LPS-stimulation (Fig. 2C),
but 6 h after IFNβ or IFNγ stimulation, demonstrating an indirect
mechanism of activation by IFNs. PI3K (through induction of tyrosine
phosphorylation of TLR3) has been shown to enhance IRF3 phosphor-
ylation and subsequent gene induction (Sarkar et al., 2004). GSK3β, a
multifunctional kinase implicated in HIV-mediated neuropathogen-
esis (Dewhurst et al., 2007), was phosphorylated (therefore inacti-
vated) by PIC or LPS (pSer9-GSK3β), while IFNs had minimal effects
(Fig. 2C).
PIC and LPS in microglia additionally induced expression of anti-
viral proteins and transcription factors (Fig. 2D). Viperin (also called
cig5) (Chin and Cresswell, 2001) and indoleamine 2,3 dioxygenase
(IDO), which we have identiﬁed as PIC-inducible anti-HIV proteins in
Fig. 2. Microglial cell signaling pathway activation by PIC or LPS: (A) nuclear proteins
from microglial cultures stimulated with PIC or LPS for various time periods were
analyzed by Western blot. Nuclear IRF3 was detected early, whereas pY-Stat1 was
detectable 6 h after stimulation with PIC. (B) Western blot was performed using whole
cell lysates. PIC activates all three MAP kinases within 10 min. (C) Microglial cultures
were treated with PIC (10 μg/ml), LPS (100 ng/ml), IFNβ (10 ng/ml) or IFNγ (10 ng/ml)
for 20min to 6 h andWestern blot analysis was performed for p-Erk, pS-Stat1, p-Akt and
pSer9-GSK3β, as described in the Materials and methods. While PIC and LPS activation
proﬁles are similar, IFNβ and IFNγ show distinctly different cell activation proﬁles. See
text for details. (D) Microglia were subjected to longer (6 h to 3 days) treatment with
LPS or PIC, or IFNβ or IFNγ and their protein expression was analyzed in two separate
blots. Transcription factors, Stat1 and C/EBPβ, as well as the inducible IRF3 kinase, IKKɛ
(also called IKKi), were induced similarly by LPS or PIC. LPS and PIC also showed similar
induction of viperin (cig5) and IDO with respect to the amounts and kinetics. On the
other hand, IKKɛ and viperin were induced preferentially by IFNβ, while IDO was
induced preferentially by IFNγ. Total Stat1 and C/EBPβ were induced by both IFNs.
Whole cell lysates were used for Western. The 37 kDa and 20 kDa mark the putative
activatory and inhibitory C/EBPβ isoforms, respectively.
Fig. 3. HIV-induced microglial cell activation: (A) microglia infected with VSVg env HIV
for 6 h–4 days were analyzed for the expression of HIV gag (p24), IRF3, viperin and
Stat1. HIV gag induction was visible within 1 day and increased through 4 days. IRF3
showed time-dependent decrease. Viperin was induced strongly by HIV and showed
biphasic kinetics. Stat1 protein was upregulated by HIV. (B) Microglia infected with
HIVADA were analyzed as in (A). No detectable p24 productionwas noted even at 5 days
post-inoculation. The p24 levels at 6 h and 1 day represent input virus (blot over-
exposed). IRF3 showed time-dependent decrease. Viperin showed only the early phase
of induction. T-stat1 showed upregulation. The numbers below IRF3 blots are
densitometric ratios to protein loading controls.
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by PIC and LPS in microglia. IFNβ and IFNγ preferentially induced
viperin and IDO, respectively. Transcriptional factors involved in TLR/IFN signaling were upregulated. Stat1 (and Stat2, not shown) was
upregulated by all four stimuli, whereas IKKɛ (an IRF3 kinase) was
upregulated by LPS, PIC and IFNβ but not by IFNγ. Macrophage
inﬂammatory gene activator and HIV transactivator C/EBPβ was
induced similarly by all four stimuli, including the 37 kDa activating
and the 20 kDa inhibitory isoforms. Thus, a systematic survey of the
cell signaling pathways in primary human microglia has shown that
TLR3 and TLR4 trigger multiple cell activation pathways in a strikingly
similarmanner, accounting for their similar antiviral activity as well as
gene induction (see below).
HIV-induced microglial cell activation (Figs. 3A and B)
Viral intermediary dsRNA could activate cells via TLR3 or RIG-I-like
helicases (RLR) (Akira et al., 2006; Hiscott et al., 2006; Sen and Sarkar,
2005), but currently there is no evidence that HIV can trigger dsRNA
receptors (thereby activating IRF3) (Okumura et al., 2008; Brown
et al., 2008). Instead, evidence suggests that HIV and other viruses
induce degradation of IRF3 in infected cells (Okumura et al., 2008; Lin
et al., 1998). In order to examine the relationship between HIV- and
dsRNA-induced cell activation, we performed the following experi-
ments. Microglia were infected with VSVg env HIV or R5 HIV (HIVADA)
for 6 h to 5 days and Western blot analysis was performed for HIV gag
and microglial antiviral proteins. As shown in Fig. 3A, HIV gag was
induced within 1 day and increased through 4 days (latest time point)
following VSVg HIV infection. In HIVADA-infected microglia, p24 was
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(6 h and 1 day) p24 levels represent input virus (blot over-exposed).
In both cultures, endogenous IRF3 in microglia showed a time-
dependent decrease. In contrast, viperinwas induced by VSVg HIV in a
biphasic manner (6 h, 1 day and 4 days), whereas only the early phase
(6 h, 1 day) was apparent in HIVADA-infected microglia. These results
suggest a dual mechanism for viperin induction by HIV, one triggered
by early intracellular events of the HIV life cycle, and the other by late
productive HIV infection (also see Fig.1D). Unlike viperin, IDOwas not
induced in either HIV-infected culture (not shown, also see below
Fig. 4B). Microglial Stat1 protein was induced by both HIV types
with similar kinetics (also see below Fig. 5). Stat1 protein induction
by HIV has been shown previously (Johnston et al., 2000). Together,
our results show that HIV-induced microglial gene induction is dis-
tinct from that by PIC and support that HIV does not activate IRF3
(Okumura et al., 2008).Fig. 4. Role of IRF3 in the induction of IFNβ and anti-HIV activity. (A) Microglia were ﬁrst inf
thenwith HIVADA or not in the presence or absence of PIC for 3 h. Q-PCR analysis was perform
PIC-induced HIV suppressionwas examined by transductionwith adenovirus DN- orWT-IRF3
3 days. Over-expression of IRF3 was conﬁrmed by Western blot for the WT or N-termina
expression was reversed. IDO was not induced by HIV alone, but was induced by PIC, and th
expressing microglia.Role of IRF3 in the induction of IFNβ and anti-HIV activity (Figs. 4A and B)
We next asked whether IRF3 plays a role in PIC-induced IFNβ
expression and HIV suppression, by adopting adenovirus-mediated
over-expression of dominant negative (DN) and wild-type (WT) IRF3
(Rivieccio et al., 2005). Microglia were ﬁrst infected with adenovirus
for 3 days, then with HIVADA in the presence or absence of PIC for 3 h
(optimal time point for IFNβ mRNA). Q-PCR analysis was performed
(Fig. 4A). The results were notable for upregulation of (adenovirally
transduced) IRF3 (both DN and WT) by PIC treatment (pb0.001,
t-test). High levels of IFNβ mRNA were induced by PIC (but not by
HIV) and this was almost completely inhibited by DN-IRF3 (pb0.001,
t-test). A modest level of induction by PIC was demonstrated for IDO,
IP-10/CXCL10, Rantes/CCL5 and TNFα mRNA (3 h time point), with
relatively little or no change by DN-IRF3 (WT versus DN: pN0.05, not
signiﬁcant). HIV induced only IP-10 mRNA. These results togetherected with adeno-IRF3 (DN: dominant negative IRF3, or WT: wild-type IRF3) for 3 days,
ed as described in the Materials andmethods using GAPDH as control. (B) Role of IRF3 in
, as in (A), followed by infectionwith VSVg envHIVwith or without PIC for an additional
l truncated (DN) IRF3. In DN-IRF3 over-expressing microglia, the effect of PIC on p24
e amount was reduced in DN-IRF over-expressing microglia, compared to WT-IRF over-
Fig. 5. PIC signaling in HIV-infected and uninfected microglia: microglia were infected
with VSVg env HIV (or VSVg env only, mock) for 3 days, and then stimulated with PIC
for indicated time periods (0–24 h). Western blot analysis was performed for HIV and
microglial proteins. HIV induced viperin and Stat1 but not IDO, and PIC stimulation by
24 h did not result in signiﬁcant changes in the level of these proteins compared to
mock-infection. Probing for some of the signaling proteins demonstrated that p-Erk, p-
Akt, and p-GSK3βwere activated normally in HIV-infectedmicroglia, albeit with a slight
increase in levels compared to mock-infection. Notably, p-eIF2α showed transient
suppression at 1 h and 6 h in infected cells, which recovered by 24 h. Densitometric
ratios to vinculin are shown for p-Erk and p-eIF2α.
Fig. 6. PIC activates microglial TLR3. Microglia were transfected with TLR3-speciﬁc
siRNA or control siRNA at 10 or 30 nM for 3 days and then stimulated with PIC for 6 h, as
described in the Materials and methods. Transcripts for TLR3, IFNβ, IDO and viperin
were measured by real-time PCR with PBDA as a control. Silencing microglial TLR3 with
speciﬁc siRNA (more effective at 10 nM) reducedmicroglial expression of all four genes.
The suppression of viperin was less effective. Data are normalized to the transcript
levels present in PIC-treated, control-siRNA transfected microglia. These results show
that PIC activates microglia primarily through TLR3.
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glial gene expression and that the induction of IFNβ (but not other
genes) was greatly dependent on IRF3.
To determine the role of IRF3 in HIV replication, we examined the
level of HIV gag inmicroglial cultures infected with VSVgHIV±PIC (in
addition to adenoviral infection as described above) for an additional
3 days (Fig. 4B). Over-expression of DN (N-terminal truncated) and
WT-IRF3 was conﬁrmed by Western blot analysis (Fig. 4B). The levels
of over-expressed IRF3 proteins were higher in the presence of PIC,
conﬁrming the results with Q-PCR (Fig. 4A). The amount of HIV gag
(p55+p24) expression was greater in DN-IRF3-expressing microglia
comparedwithWT-IRF3-expressingmicroglia, both in the presence or
absence of PIC. Together, these results indicate an anti-HIV role of IRF3
in microglia, most like through the induction of antiviral proteins such
as IFNβ. The Western results for IDO (Fig. 4B) essentially reﬂect the
mRNA results shown in Fig. 4A.
TLR3 signaling is altered minimally in HIV-infected microglia (Fig. 5)
We next asked whether HIV can alter PIC-induced microglial
activation. Microglia were infected with VSVg env HIV (or mock-
infected using VSVg env protein only) for 3 days, then stimulated with
PIC (Fig. 5). HIV gag (p24) expressionwas downregulated by PIC even
though PIC was added 3 days after infection, showing complete
inhibition by 24 h (compare with kinetics of HIV gag accumulation
without PIC in Fig. 3A, for example). Similar to results in Figs. 2–4, HIV
infection induced the expression of viperin and Stat1 but not IDO in
microglia, with minimal changes noted at 20 min–6 h after PIC
treatment. By 24 h, there was little or no difference between mock-
infected and HIV-infected microglia in the expression of all three
proteins. Examination of several phosphoproteins (p-Erk, p-Akt and
p-GSK3β) demonstrated that they were variably induced by HIV, but
that both mock- and HIV-infected cells showed similar kinetics of
induction by PIC, with slightly elevated levels in HIV-infected cells
compared to mock. p-eIF2α (a PKR substrate) induction by PIC wastransiently suppressed at 1 h and 6 h in HIV-infected microglia
(n=3), but showed recovery by 24 h, by which time HIV gag was
completely inhibited. These results together demonstrate that TLR3
signaling is minimally altered in HIV-infected microglia and that PIC
can overcome the mechanism(s) elicited by HIV to counteract host
antiviral immunity and can inhibit HIV replication.
PIC-induced gene expression is suppressed by TLR3 silencing (Fig. 6)
Since dsRNA can activate cytosolic dsRNA sensors (RIG-I-like heli-
cases: RLR) (Akira et al., 2006; Hiscott et al., 2006; Sen and Sarkar,
2005), in addition to endosomally located TLR3, we directly deter-
mined the role of TLR3 in PIC-induced microglial activation by RNAi.
Microglia were transfected with TLR3-speciﬁc siRNA or control siRNA
at 10 or 30 nM for 3 days then stimulated with PIC for 6 h. Transcripts
for TLR3, IFNβ, IDO and viperinweremeasured by Q-PCRwith PBDA as
control. Fig. 6 shows that TLR3-speciﬁc siRNA at 10 nM strongly
reduced microglial expression of all four genes (pb0.001) (Rivieccio
et al., 2006), demonstrating that PIC acted primarily through TLR3 in
microglia. siRNA at 30 nM was less effective than 10 nM, as reported
previously in astrocytes (Rivieccio et al., 2006).
Gene expression proﬁles of PIC or LPS-activated microglia
(Fig. 7 and Table 1)
The high similarity between PIC- and LPS-activated microglia with
respect to their antiviral activity and intracellular signaling suggested
that they might modulate similar sets of microglial genes. In order to
test this, microarray analysis was performed employing the 27k human
cDNA array obtained from the Albert Einstein College of Medicine
Microarray Facility. RNA was harvested at 6 h and 16 h after PIC or LPS
stimulation and unstimulated microglia were used as control. A large
number of genes were upregulated or downregulated by PIC or LPS at
each time point. For example, 1874 genes were upregulated and 2926
252 H.-S. Suh et al. / Virology 392 (2009) 246–259genes were downregulated by PIC at 6 h time point using Cy5/Cy3
ratios of 1.5 and 0.67, respectively. The genes were grouped into several
categories based on their known function and heat maps were
generated to aid visualization of the gene expression pattern. The
partial results (cytokines, chemokines, and IFN-related genes) are
shown in Fig. 7 and Table 1, and the complete data sets are available in
the Supplementary material. They show that the gene expression
proﬁles of PIC- and LPS-activated microglia were remarkably similar,
with regard to the types of genes induced (or suppressed) and the
amounts and kinetics of change, with some minor differences (see
below). The expression of many of the cytokines, chemokines and IFN-
related genes was conﬁrmed by Q-PCR, RPA, Western blot analysis and
ELISA (Figs. 3, 5 and 6, and data not shown). The fold changeFig. 7. Microarray proﬁles of TLR3- or TLR4-activated microglia: microglia were activated
microarray analysis as described in theMaterials andmethods. Heat maps were generated for
genes (A–C). For details, refer to Table 1 (genes are listed in order of appearance in Fig. 7), an
each column represents a time point. Red indicates increased expression of the gene relativdetermined by microarray (rarely over 100 fold) was often an
underestimation, since with Q-PCR or ELISA, the fold changes often
reached the range of hundreds to thousands (ﬁgures, and data not
shown). Similar underestimations of differential gene expression using
DNA microarrays compared to more conventional technologies have
been reported previously (Taniguchi et al., 2001).
Cytokines
Proinﬂammatory cytokines (IL-1α, IL-1β, TNFα and IL-6) were
highly induced by PIC and LPS inmicroglia, with LPS being more potent
than PIC by a factor of 1.1 to ∼3.5 (Table 1). The reverse was true for the
Th2 cytokine IL-13, and IL-1 receptor antagonist (PICNLPS). The mRNAby PIC (10 μg/ml) or LPS (100 ng/ml) for 6 h or 16 h, and total RNA as harvested for
the three broad categories of genes belonging to cytokines, chemokines and IFN-related
d the text. Each row in the heat map diagram represents a single gene in the signature;
e to the untreated control; green indicates decreased expression.
Table 1
Gene expression in microglia activated by TLR3 or TLR4 ligand.a
Name PIC 6 h PIC 16 h LPS 6 h LPS 16 h
Cytokines TNFRSF7 0.17 0.37 0.14 0.69
IL16 0.45 1.48 0.29 1.41
IL13 6.48 41.04 7.73 11.37
TNFSF10 2.53 7.19 1.76 1.44
TNFSF2 76.96 1.99 92.78 2.13
IL7R 1.66 1.05 3.63 1.09
IL6 225.77 15.78 379.04 28.01
IL23A 10.05 1.39 41.78 2.26
IL1B 120.97 30.07 171.80 62.47
IL1A 112.12 12.78 153.53 44.11
IL15RA 18.61 15.76 34.00 4.38
IL15 2.60 2.37 5.49 1.48
IL13RA1 0.41 0.38 0.39 0.30
IL1RN 49.38 44.78 46.38 23.86
TNFSF12–13 0.33 0.47 0.56 0.78
Chemokines CCL25 0.25 0.68 0.24 0.66
CCL8 2.02 23.01 0.90 17.77
CCL7 2.27 10.93 1.69 14.32
CCL2 2.65 3.36 1.07 5.13
CXCL11 4.94 26.75 5.00 2.99
CCL5 18.10 21.43 24.79 8.81
CXCL10 43.48 162.11 41.08 10.05
CXCL9 2.04 5.14 2.04 1.39
CXCL3 62.89 1.26 66.23 6.08
CXCL1 23.20 1.01 24.72 3.10
CCR-like 2 10.30 2.66 13.63 1.77
CCR7 32.11 17.30 81.67 5.53
CXCL12 0.32 0.32 0.45 0.43
IFN-related STAT2 1.53 3.06 2.01 2.12
IFITM3 5.16 18.83 5.62 14.13
IFITM1 6.92 42.42 7.85 15.40
TLR3 1.00 3.14 0.78 1.40
STAT1 3.98 10.95 2.47 5.40
IFI6 4.37 8.23 3.57 4.84
IFNAR1 0.26 0.40 0.40 0.51
IFNGR1 0.11 0.31 0.11 0.39
IRF2BP2 0.22 0.53 0.23 0.74
IRF7 5.80 5.91 13.41 4.61
GBP1 6.97 9.48 15.37 2.98
MX1 39.08 43.40 44.13 23.35
ISG20 20.12 30.00 33.80 11.77
ISG15 21.45 30.72 30.02 11.71
IFI44 7.31 12.74 11.30 5.38
OAS1 3.02 5.40 3.57 2.66
IFI35 2.63 3.81 5.56 3.49
IRF8 0.51 0.26 0.33 0.19
MX2 20.52 14.84 19.29 8.65
IFRD1 5.65 2.42 3.96 2.12
OAS2 14.27 12.40 12.16 6.16
IFIT3 10.81 10.20 7.95 3.89
IFIT5 4.30 2.89 6.14 1.96
GBP2 8.84 4.08 11.44 1.97
IRF5 35.99 5.98 50.29 16.42
NMI 4.00 5.59 3.87 3.13
IFIT2 16.14 43.17 14.41 4.75
IFIT1 25.28 73.31 16.21 19.87
a Microarray proﬁles of microglia activated by PIC (10 μg/ml) or LPS (100 ng/ml) for
6 h or 16 h as shown in Fig. 7. The numbers represent fold induction over control (un-
activated) microglia.
Table 2
Gene expression in microglia infected with HIV (VSVg env NL4.3) for 24 h.
Gene name Fold changea
Cytokines IL-1β 1.58
IL-1RN (IL-1 receptor antagonist) 3.03
IL-13 1.67
IL-10RA (IL-10 receptor, alpha) 0.64
Chemokines CXCL10 (IP-10) 5.30
CCL5 (Rantes) 1.90
IFN-related genes ISG15 1.50
ISG20 1.00
OAS1 1.50
OAS2 1.30
GBP2 1.65
Mx2 1.70
IFIT1 (p56) 1.53
IFIT2 (p54) 1.77
IFIT5 1.86
IFITM1 2.18
IRF7 2.03
STAT2 1.65
eIF2α K2 (eukaryotic translation
initiation factor 2α-kinase 2)
1.59
a Microglia were either uninfected or infected with VSVg env HIV at high
concentrations for 24 h, then RNA harvested for microarray analysis as described in
the Materials and methods. Fold change in HIV-infected microglia over control,
uninfected microglia.
253H.-S. Suh et al. / Virology 392 (2009) 246–259for IL-13 receptorwas suppressed by both. The Th1 cytokine IL-23 (p19)
was induced by both (LPSNPIC) but IL-12 was not detected. IL-15, a
cytokine that is induced by LPS in vivo and mediates glial activation
(Gomez-Nicola et al., 2008), is also highly induced by both. IL-15
receptor was also strongly induced by both PIC and LPS.
Chemokines
Among the most highly upregulated chemokines were the IRF3-
dependent (IRF3-enhanced) gene IP-10 (CXCL10), and the related
CXCR3-binding chemokines, Mig (CXCL9) and I-TAC (CXCL11), all of
which were induced more by PIC than LPS, especially at 16 h. Rantes
(CCL5) showed a similar trend. The GRO oncogenes (CXCL1 andCXCL3)were very highly induced by PIC and LPS at 6 h, with persistent
elevation by LPS but not by PIC. The monocyte chemoattractant pro-
teins (MCP) 1, MCP2 and MCP3 (CCL2, CCL8, and CCL7, respectively)
were also upregulated at 16 h, with no clearly discernible pattern of
induction by the two TLR ligands. CCR7, a dendritic cell antigen that is
expressed in microglia in inﬂamed CNS (Seraﬁni et al., 2006; Dijkstra
et al., 2006), is highly induced. Stromal derived factor (SDF-1: CXCL12)
and the recently discovered chemokine CCL25 were downregulated.
IFN-related genes
IFN-related genes included those involved in the activation of type
I IFN genes and IFN signaling, as well as IFN-stimulated genes (ISGs)
involved in antiviral responses. These were among the most highly
induced genes in both PIC and LPS arrays. These included Stat1 and
Stat2 involved in IFN signaling, IRF7 involved in TLR3 (and other TLR)
signaling, as well as TLR3 itself, which was induced by PIC only at 16 h.
IFNβ was not detected reﬂecting early peak (1–3 h) and low sensi-
tivity of microarray (Taniguchi et al., 2001). ISGs such as Mx1 and
Mx2, OAS1 and OAS2, as well as GBP1 and GBP2 were all highly
induced, with PIC being more potent than LPS (16 h). The IFN-induced
protein with tetratricopeptide (IFIT) family genes (Sen and Peters,
2007) were the most highly induced of this gene category. IFIT1 (p56)
and IFIT2 (p54), known IRF3-dependent genes, were highly induced,
with PIC more potent than LPS (up to ∼10-fold at 16 h). IFN-induced
transmembrane proteins, IFITM1 and IFITM3, were also highly
induced with PIC more potent than LPS at 16 h. ISG15 and ISG20,
also known IRF3-dependent genes (Grandvaux et al., 2002), followed
the same pattern. By contrast, IFN regulatory factor 2 (IRF2) binding
protein 2 (IRF2BP2), a protein involved in downregulation of IFN
signaling, was suppressed, as was IRF8 (also called IFN consensus
sequence binding protein: ICSBP), a myeloid and lymphocyte protein
involved in cell proliferation, differentiation and innate immunity
(Huang et al., 2008). The type I IFN receptor (IFNAR1) and IFNγ
receptor (IFNGR1) were downregulated by both PIC and LPS.
HIV-induced genes (Table 2)
To determine the extent to which HIV can elicit gene expression,
microarray was performed with VSVg env HIV-infected microglia
(24 h). As shown in Table 2, a small number of genes belonging to
254 H.-S. Suh et al. / Virology 392 (2009) 246–259cytokines (IL-1β, IL-1ra and IL-13), chemokines (IP-10/CXCL10 and
Rantes/CCL5) and IFN-related genes (ISG15, OAS1, GBP1, IFIT1, IFIT2,
IFIT5, and IFITM1, and IRF7) were induced minimally by HIV, with the
exception of IP-10 (over 5-fold). The microarray data set is available
online (Supplementary data).Table 3
Genes differentially regulated in DN-IRF3- and WT-IRF3-over-expressing microglia.a
Gene function Gene symbol Gene name
A. Decreased genesa
Chemokines and receptors CXCL10 chemokine (C-X-C
CXCL11 chemokine (C-X-C
CXCL9 chemokine (C-X-C
CCL5 chemokine (C-C mo
CCR7 chemokine (C-C mo
Cytokines and receptors IL-1ra interleukin 1 recep
TRAIL tumor necrosis fact
CD40 CD40 molecule (TN
IL-13 interleukin 13
Antiviral and interferon-induced IFIT1 interferon-induced
IFIT2 interferon-induced
IFITM1 interferon-induced
IFI44L interferon-induced
ISG15 ISG15 ubiquitin-like
ISG20 interferon-stimulat
OAS1 2′,5′-oligoadenylate
Mx2 myxovirus (inﬂuen
GBP1 guanylate binding p
GBP2 guanylate binding p
IDO indoleamine-pyrrol
APOBEC3A apolipoprotein B m
APOBEC3G apolipoprotein B m
CUL5 cullin 5
Antiviral signaling TLR7 toll-like receptor 7
TANK TRAF family memb
MyD88 myeloid differentia
IRF7 interferon regulator
STAT2 signal transducer an
eIF2αK2 eukaryotic translati
Miscellaneous CD38 CD38 molecule
CD83 CD83 molecule, tra
CD86 CD86 molecule, tra
ICAM5 intercellular adhesi
HK2 hexokinase 2
IER2 immediate early re
MPEG1 macrophage expres
GRIN1 glutamate receptor,
ATF3 Activating transcrip
B. Increased genesa
Cytokines, chemokines and receptors CCL18 chemokine (C-C mo
CXCL1 chemokine (C-X-C
(GRO1, GROα)
CXCL3 chemokine (C-X-C
IL-1α interleukin 1, alpha
IL-1β interleukin 1, beta
TNFRSF1B tumor necrosis fact
Growth factors and receptors CSF3 colony stimulating
CSF-1R colony stimulating
oncogene homolog
Inﬂammatory enzymes COX2 prostaglandin-endo
(PTGS2)
MMP1 matrix metallopept
Transcription factors and signaling HIF1α hypoxia-inducible f
transcript variant 1
BCL6 B-cell CLL/lymphom
RPS6KA1 (S6Kα1) ribosomal protein S
FKBP5 FK506 binding prot
Macrophage antigens CD163 CD163 molecule, tr
CD14 CD14 molecule, tran
MMD monocyte to macro
SDC2 syndecan 2
a Microglia were infected with adenovirus carrying DN-IRF3 orWT-IRF3 plasmid for 3 days
described in the Materials and methods. Values are ratios in DN-IRF3-over-expressing m
dependent (enhanced) gene, and highly positive values suggest genes suppressed by WT-IRAlteration of microglial gene expression by DN-IRF3 and WT-IRF3
(Table 3)
To examine the role of IRF3 in PIC, LPS and HIV-induced microglial
gene expression, we performed microarray analyses of microgliaFold
change
motif) ligand 10 (IP-10) 0.03
motif) ligand 11 (I-TAC) 0.04
motif) ligand 9 (Mig) 0.24
tif) ligand 5 (Rantes) 0.28
tif) receptor 7 0.33
tor antagonist, transcript variant 3 0.27
or (ligand) superfamily, member 10 (TNFSF10) 0.09
F receptor superfamily, member 5), transcript variant 1 0.24
0.33
protein with tetratricopeptide repeats 1, transcript variant 2 0.16
protein with tetratricopeptide repeats 2 0.08
transmembrane protein 1 (9–27) 0.31
protein 44-like 0.34
modiﬁer 0.30
ed exonuclease gene 20 kDa 0.15
synthetase 1, 40/46 kDa (OAS1), transcript variant 1 0.65
za virus) resistance 2 (mouse) 0.45
rotein 1, interferon-inducible, 67 kDa 0.34
rotein 2, interferon-inducible 0.40
e 2,3 dioxygenase 0.49
RNA editing enzyme, catalytic polypeptide-like 3A 0.24
RNA editing enzyme, catalytic polypeptide-like 3G 0.28
0.41
0.30
er-associated NFKB activator, transcript variant 1 0.47
tion primary response gene (88) 0.56
y factor 7 (IRF7), transcript variant d 0.57
d activator of transcription 2, 113 kDa 0.33
on initiation factor 2-alpha kinase 2 0.48
0.18
nscript variant 1 0.48
nscript variant 2, mRNA 0.42
on molecule 5, telencephalin 0.23
0.40
sponse 2 0.43
sed gene 1 0.45
ionotropic, N-methyl d-aspartate 1, transcript variant NR1-1 0.47
tion factor 3, transcript variant 4 0.22
tif) ligand 18 (pulmonary and activation-regulated) 3.57
motif) ligand 1 (melanoma growth stimulating activity, alpha) 5.14
motif) ligand 3 (GRO3, GROγ) 8.09
4.35
7.74
or receptor superfamily, member 1B (TNFR2) 8.19
factor 3 (granulocyte, G-CSF), transcript variant 2 2.67
factor 1 receptor, formerly McDonough feline sarcoma viral (v-fms) 5.64
peroxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) 4.81
idase 1 (interstitial collagenase) 4.01
actor 1, alpha subunit (basic helix–loop–helix transcription factor), 2.67
a 6 (zinc ﬁnger protein 51), transcript variant 1 2.88
6 kinase, 90 kDa, polypeptide 1, transcript variant 2 (MAPKAPK1A) 2.38
ein 5 2.18
anscript variant 1 3.89
script variant 2 4.17
phage differentiation-associated 2.14
3.73
in the presence of PIC during the last 24 h, and RNA harvested for microarray analysis as
icroglia to WT-IRF3-over-expressing microglia. Highly negative values suggest IRF3-
F3. Examples of genes with negative values are listed in (A) and positive values in (B).
255H.-S. Suh et al. / Virology 392 (2009) 246–259transduced with adenoviral vectors (DN-IRF3 or WT-IRF3). A set of
microglia were ﬁrst transduced with adenovirus (DN-IRF3 or WT-
IRF3) for 3 days and then were exposed to PIC, LPS, HIV or none
(control). Gene expression in DN-IRF3-over-expressing microglia
was analyzed against that in WT-IRF3-over-expressing microglia,
with an assumption that a value of less than 1 would indicate an
IRF3-dependent (IRF3-enhanced) gene.
We indeed observed highly negative values for known IRF3-
dependent genes in these experiments (Table 3A). Interestingly, many
of these genes were also present in control microglia that were not
exposed to any of the stimuli (TLR ligands or HIV, data not shown),
indicating that over-expressed WT-IRF3 was also active. Furthermore,
we also observed a subset of genes with positive values, suggestive of
inhibition by over-expressed WT-IRF3 (Table 3B). A complete micro-
array data set is available as Supplementary data.
Discussion
Microglia are innate immune cells in the brain engaged in antiviral
responses. Of the 11 TLRs, TLR3 and TLR4 are unique in that they can
transmit signals through the MyD88-independent (Akira et al., 2006),
TRIF-dependent pathway resulting in the activation of IRF3 and IFNβ
gene expression. This latter aspect critically contributes to antiviral
immunity. In order to gain insight into the speciﬁc TLR signaling
pathways that regulate gene expression and antiviral activity, human
fetal microglia were challenged with speciﬁc TLR ligands PIC and LPS,
and their responses were compared using several different
approaches. First and foremost, our results showed that TLR3 and
TLR4 activate antiviral immunity in microglia. PIC and LPS suppressed
HIV expression in microglia in both the acute spreading infection
model as well as the single-cycle infection model.
Our study indicates that the role of macrophage activators in
macrophage HIV infection could vary depending on the types of
infection. It is generally believed that unlike interferons which have
known antiviral activity, LPS and proinﬂammatory cytokines enhance
HIV expression (Osiecki et al., 2005; Folks et al., 1989; Rosenberg and
Fauci, 1990). However, much of these data were derived from cell
lines or cells with stably integrated HIV proviruses, such as U1 cells
(monocytic), ACH-2 cells (T cell line) or HIV-transgenic murine
macrophages (Sun et al., 2008; Equils et al., 2003). In fact, we ﬁnd that
in U1 cells, both LPS and IL-1 robustly activate HIV expression, and PIC
fails to inhibit HIV, unlike in microglia. Indeed, several TLR ligands
including those that bind TLR3, TLR7/8 and TLR9 have been shown to
enhance HIV/SIV in chronically-infected cell lines (Lester et al., 2008;
Scheller et al., 2004; Schlaepfer et al., 2006; Equils et al., 2003),
whereas their effects are inhibitory in acute infection models (Barber
et al., 2004). We and others also ﬁnd that proinﬂammatory cytokines
including IL-1β, TNFα and IL-6 suppress HIV expression in microglia
(Si et al., 2004 and unpublished). These results indicate that cytokines
and TLR ligands play different roles in HIV replication depending on
the types of infection, and call for caution in extrapolating data from
different infection models (Wang et al., 2004; Scholle and Mason,
2005; Tabeta et al., 2004; Zucchini et al., 2008).
In addition to TLR3 and TLR4, we also tested the role of the TLR9
ligand CpG ODN in microglial HIV expression and found it to be
suppressive. However, the control GpC ODN also suppressed HIV
expression in microglia, suggesting that the antiviral effect of CpG
ODN was primarily mediated by phosphorothioate modiﬁcation
rather than through activating TLR9. Similar non-speciﬁc effects of
the TLR9 ligand ODNs have been documented by other investigators in
PBMCs with respect to antiviral activity and cytokine expression
(Schlaepfer et al., 2004; Wang et al., 2005).
Viruses can activate host cell TLRs and other viral sensors through
formation of viral PAMPs. Therefore, one of the questions we
attempted to address in our study was whether HIV can activate IRF3
through either TLR3 or the alternative cytosolic dsRNA sensor “RIG-likehelicases or RIG-like receptors (RLR)” (Kato et al., 2005; Sen and
Sarkar, 2005; Hiscott et al., 2006). Since both types of dsRNA receptors
activate IRF3, we examined gene expression proﬁles with particular
focus on IRF3-dependent genes. Minute amounts of induction were
observed including IFIT1, IFIT2 and ISG15, and although this does not
completely exclude TLR3/RLR activation, it is unlikely that this will
amount to signiﬁcant antiviral immunity. Our analyses also demon-
strated similarities and differences between HIV-infected microglia
and PIC-activated microglia. The proteins robustly induced by HIV
including viperin, Stat1 and IP-10 are all IFN-inducible genes (Rivieccio
et al., 2006; Hua and Lee, 2000), and HIV did not induce IRF3-
dependent genes (such as IFNβ) in signiﬁcant quantities. These
quantitative differences in antiviral genes lead to different outcomes,
as we have observed that IL-1- (as opposed to PIC-) stimulated astro-
cytes have no antiviral activity, although IL-1 induced IRF3 activation
and IFNβ production (Rivieccio et al., 2006). Furthermore, in addition
to the lack of IRF3-dependent gene induction by HIV, our analysis also
revealed that the amounts of IRF3 protein in HIV-infected microglia
decreased with time, and this appeared to be independent of viral
replication. Together, these results support the conclusions of the
recently published studies which demonstrated that HIV does not
activate IRF3 but rather causes its degradation (Okumura et al., 2008;
Brown et al., 2008). It is possible that the reported type I interferon
(IFNα) induction by HIV is triggered by other viral sensors such as
TLR7/8 (Heil et al., 2004; Beignon et al., 2005). As for the role of TLR3
versus RLR in microglial cell signaling by PIC, our RNAi data support a
predominant role of TLR3, consistent with the literature (Town et al.,
2006). However, these results do not exclude the role for RLR. Indeed,
our microarray analysis show that microglia express RIG-I which is
further upregulated by PIC (data not shown).
We have also attempted to examine whether HIV-infected micro-
glia are defective in antiviral immunity conferred by PIC, by examining
HIV gag expression, as well as comparing PIC-induced cell signaling
and protein expression in infected and uninfected cells. Minor
differences notwithstanding, these results seem to indicate that
dsRNA-activated antiviral immunity is intact in HIV-infected micro-
glia, as viral replication was suppressed even when PIC was added
days after HIV infection.
We have performed gene proﬁling studies, as well as Western blot
analysis, ribonuclease protection assays, and ELISA of antiviral and
cytokine/chemokine genes (Fig. 2 and data not shown) to contrast the
TLR3- and TLR4-induced microglial activation. Activation of NF-κB
(not shown), IRF3, MAP kinases, p-Akt, p-GSK3β, and C/EBPβ, all
occurred similarly, with minor variations. Induction of several
proteins involved in antiviral immunity and signaling were also very
similar, and these included Stat 1, IKKɛ (IRF3 kinase), viperin (type I
IFN-induced protein with antiviral properties)63, and IDO (type II
IFN-induced protein with tolerogenic and antiviral properties)
(Rivieccio et al., 2006; Suh et al., 2007). These results were rather
surprising because TLR4 activates the classical MyD88-dependent NF-
κB activation, in addition to the TRIF-dependent NF-κB/IRF3 activation
pathway. We do not believe the PIC and LPS preparations are cross-
contaminated, because astrocytes did not respond to LPS, while they
responded robustly to PIC. Previously, the use of gene deletion
strategy in mice permitted dissection of the relative contribution of
the MyD88-dependent and MyD88-independent pathways in NF-κB
activation and gene expression, and earlier studies of murine macro-
phages indeed have found MyD88 to be necessary for proinﬂamma-
tory cytokine induction by LPS (Kawai et al., 1999). However, a recent
study demonstrated cytokine production by MyD88-deﬁcient murine
microglia (although in smaller quantities) (Esen and Kielian, 2006)
and our results also suggest a relatively minor role the MyD88 path-
way plays in TLR4-induced gene expression inmicroglia. We speculate
that one of the variables that might contribute to this discrepancymay
be the amount of macrophage differentiation, as monocytes do not
express TLR3 and respondminimally to PIC (Jack et al., 2005; Muzio et
256 H.-S. Suh et al. / Virology 392 (2009) 246–259al., 2000), suggesting that in monocytes, the TLR4 activation pathway
is skewed toward the MyD88-dependent pathway.
Our results also suggest that microglial TLR3 activation may have
consequences that are as deleterious as TLR4 activation, i.e., chronic
inﬂammatory activation of the CNS leading to neurodegeneration.
Indeed, these undesirable long-term consequences of dsRNA (PIC)
have been documented. Injection of PIC to pregnant mice has been
shown to produce schizophrenia-like disease in the offspring mice
(Patterson, 2007), and chronic exposure of mice to PIC produces
distinct CNS abnormalities termed “sickness behavior” (Cunningham
et al., 2007). These ﬁndings suggest that while it would be desirable to
activate the innate immune response through TLR3 or TLR4, it would
also be necessary to suppress the proinﬂammatory activity induced by
TLR signaling. In this context, it was interesting to observe that over-
expression of IRF3 in microglia led to increase in IRF3-dependent
antiviral genes including IFNβ andmany ISGs, while suppressing IRF3-
independent (but NF-κB-dependent) genes (Table 3 and data not
shown). Suppression of NF-κB-dependent genes in IRF3-over-expres-
sing cells has been observed previously (Elco et al., 2005) and this
aspect merits further investigation since those suppressed by IRF3
over-expression included proinﬂammatory genes strongly implicated
in neurodegeneration such as IL-1. These results together suggest that
IRF3 could be an ideal molecular tool by which both the increase in
innate antiviral immunity and the suppression of neuroinﬂammation
could be achieved.
Materials and methods
Human fetal microglial culture
Human CNS cell cultures were prepared from human fetal abor-
tuses as described (Lee et al., 1992; Suh et al., 2005). All tissue
collection was approved by the Albert Einstein College of Medicine
Institutional Review Board. Primary mixed CNS cultures were
prepared by enzymatic and mechanical dissociation of the cerebral
tissue followed by ﬁltration through nylon meshes of 230- and 130-μ
pore sizes. Single cell suspensionwas plated at 1–10×106 cells per ml
in DMEM (Cellgro: Dulbecco's modiﬁed Eagle medium) supplemen-
ted with 5% fetal calf serum (FCS: Gemini Bio-products, Woodland,
CA), penicillin (100 U/ml), streptomycin (100 μg/ml) and fungizone
(0.25 μg/ml) (Gibco) for 2 weeks, and then microglial cells were col-
lected by aspiration of the culture medium. Monolayers of microglia
were prepared in 60-mm or 100-mm tissue culture dishes at 1×106
cells per 10 ml medium or in 96-well tissue culture plates at 104 per
0.1 ml medium. Two to 4 h later, cultures were washed twice to re-
move non-adherent cells (neurons and astrocytes). Microglial cul-
tures were highly pure consisting of N98% CD68+ cells.
U1 cells (human monocytic cells)
The U1 cell line containing two proviral copies of HIVwas obtained
through the AIDS Research and Reference Reagent Program, Division
of AIDS, NIAID, NIH. U1 cells were cultured in complete RPMI 1640
(supplemented with 2 mM L-glutamine) supplemented with 10% FCS,
penicillin–streptomycin (100 μg/ml). Cells were seeded in 100 mm
tissue culture dishes at a concentration of 1×107 cells.
HIV viruses and microglial infection
HIVBal obtained from the AIDS Research and Reference Reagent
Program and propagated in peripheral blood mononuclear cells
(PBMC) as previously described (Si et al., 2002). HIVADAwas generated
by transfecting 293T cells with pHIVADA obtained from Dr. Mario
Stevenson, as previously described (Si et al., 2002). These viruses
infect microglia through R5 env-CCR5 mediated fusion. Microglia
were exposed to 20- to 40-ng/ml p24 HIV for 16 h at 37 °C, washed,and incubated with fresh medium. Microglial cultures were also ex-
posed to single-cycle VSVg env HIV. Single-cycle competent, vesicular
stomatitis virus (VSVg) env glycoprotein pseudotyped HIV was
produced by co-transfecting 293T cells with pNL4.3 (Nef-intact, Vpr-
intact, Env-deﬁcient) and pVSVg env (Federico et al., 2001). The
resulting viruses enter the cells through the VSVg env-mediated
pathway. Microglia were infected with ∼40 ng/ml p24 viral input that
resulted in 25% to 50% cell infection at 3 days as determined by p24
immunocytochemistry, unless otherwise stated. Mock supernatants
were prepared by treating cells in the same manner without viral
plasmids or with pVSVg env only. For microarray and real-time RT-PCR
(Q-PCR), cells were exposed to high concentrations (150–200 ng/ml
p24) of VSVg env HIV and RNA harvested at 24 h.
Role of IRF3 in PIC-induced HIV suppression was examined by
over-expression of DN- or WT-IRF3 using adenovirus-mediated gene
transfer, as previously described (Rivieccio et al., 2005). Brieﬂy,
microglia were infected with adenovirus carrying DN-IRF3 orWT IRF3
plasmids at 10 multiplicity of infection (MOI) for 3 days. Microglia
were then infected with VSVg env HIV with or without PIC for an
additional 3 days for Western blot analysis. Over-expression of IRF3
was conﬁrmed by Western blot for the WT or N-terminal truncated
(DN) IRF3. For Q-PCR, microglia were infected with HIVADA with or
without PIC for 3 h. Over-expression of IRF3 was conﬁrmed by Q-PCR.
Cell treatment with stimulants and virus
PIC and LPS were purchased from Sigma-Aldrich (St. Louis, MO).
Recombinant human IFN-γ (speciﬁc activity, 1 ng=20 U) and IL-1β
were purchased from Peprotech (Rocky Hill, NJ). IFN-βwas purchased
from PBL Biomedical Laboratories (Piscataway, NJ; 1 ng=80 U).
Microglial cultures in complete medium (DMEM+5% FCS) were
treated with PIC at 10 μg/ml, LPS at 100 ng/ml or other cytokines at
10 ng/ml. When microglia were stimulated with PIC or LPS in the
presence of HIV, input virus was washed out 24 h later and cell
stimulants were added back. TLR ligands were added together with
HIV (co-treatment) unless stated otherwise. The TLR9 ligand CpG
ODN and control GpC ODN were obtained from TIB Molbiol, MA, and
were used at a concentration of 5 μM.
Extraction of nuclear proteins
Nuclear extracts were prepared using a modiﬁed Dignam method
(Si et al., 2004). Buffers were supplemented with 1 mM PMSF, 1 mM
DTT, and a protease inhibitor mixture (Roche, Indianapolis, IN). Cells
(1×106) were scraped off in 1 mM PMSF/PBS and centrifuged. Pellets
were resuspended in low salt buffer (10 mM HEPES (pH 7.9), 1.5 mM
MgCl2, and 10 mM KCl), and allowed to sit on ice before addition of
Igepal CA-630 (Sigma-Aldrich). Samples were again pelleted and
resuspended in high salt buffer (20 mM HEPES (pH 7.9), 25% glycerol,
420 mMNaCl, and 1.5 mMMgCl2); samples were rocked gently before
ﬁnal centrifugation. The protein of nuclear extracts was quantiﬁed
using the Bradford assay.
Western blot analysis
Brieﬂy, microglial cultures in 60 mm dishes were scraped into lysis
buffer (10mMTris–HCl [pH 8.8], 50mMNaCl, 0.5 mMNa3VO4, 30mM
Na4P2O7, 50 mM NaF, 2 mM EDTA, 1% Triton X-100) at various time
points. Thirty to 70 μg of protein was separated by 10% or 12% sodium
dodecyl sulfate-polyacrylamide gel electrophoresis and then trans-
ferred to polyvinylidene diﬂuoride membrane. The blots were blocked
in Tris-buffered saline–0.1% Tween-20 containing 5% nonfat milk and
then incubated with antibodies at 4 °C for 16 h (Suh et al., 2007).
Primary antibodies included: IRF3 (C terminal; rabbit IgG which
recognizes both the endogenous and N-terminally truncated mutant
IRF3), 1/500; C/EBPβ and IKKɛ, 1/1000; (Santa Cruz Biotechnology);
257H.-S. Suh et al. / Virology 392 (2009) 246–259pJNK, p-Erk, pP38, pY-Stat1, pSer-Stat1, total Stat1, p-Akt, pGSK3β and
p-eIF2α 1/1000 (Cell Signaling); anti-p24 gag, 1/500 (DakoCytoma-
tion); IDO, 1/3000 (gift of Osamu Takikawa) (Suh et al., 2007) and
rabbit anti-viperin/cig5, 1/2000 (a gift of Keh Chuang Chin) (Chin and
Cresswell, 2001; Rivieccio et al., 2006). The secondary antibody was
horseradish peroxidase-conjugated anti-mouse or anti-rabbit IgG and
was used at 1:2000 to 1:10,000 for 1 h at room temperature. Signals
were developed using enhanced chemiluminescence (Pierce Biotech-
nology, Rockford, IL). All blots were reprobed for vinculin (117 kDa) or
β-actin using antibodies from Santa Cruz to control for protein load-
ing. Densitometric analysis was performed using Scion NIH Image
software (Scion, Frederick, MD).
RNA interference with TLR3-speciﬁc siRNA
Microglia in 60 mm dishes were transfected with 10 nM or 30 nM
human TLR3-speciﬁc small interfering RNA (siRNA) or control non-
targeting siRNA (Dharmacon, Chicago, IL) with TransIT-TKO transfec-
tion reagents from Mirus, following the manufacturer's instructions
(Suh et al., 2007). After incubation for 48 to 72 h, cells were washed
with fresh medium and then treated with PIC for 6 h. Real-time PCR
was performed to conﬁrm the expression of TLR3, IFNβ, IDO and
viperin.
Real-time PCR
Quantitative real-time reverse transcription-PCR (Q-PCR) was
performed as described previously (Suh et al., 2007; Rivieccio et al.,
2005, 2006), using porphobilinogen deaminase (PBDA) or GAPDH as
internal controls. Primer sequences for TLR3, and IFN-β, IDO and
viperin were published previously (Rivieccio et al., 2006; Suh et al.,
2007). Sequences of primers were: IRF3 [forward: caagaggctcgtgat-
ggtc; reverse: ctacccgggccatttctac], TNFα [forward ggcgtggagctgaga-
gataac; reverse ggtgtgggtgaggagcacat], and IP-10 [forward, gaatcgaa-
ggccatcaagaa; reverse, gctcccctctggttttaagg]. Brieﬂy, total RNA was
extracted from microglia in culture with TRIzol (Invitrogen Life Tech-
nologies), following the manufacturer's instructions. PCR was per-
formed using a SYBR green PCRmix and conducted with the ABI Prism
7900HT (Applied Biosystems). All values were expressed as the
increase relative to the expression of PBDA. The mean value of the
replicates for each sample was calculated and expressed as the cycle
threshold (CT; cycle number at which each PCR reaches a predeter-
mined ﬂuorescence threshold, set within the linear range of all
reactions). The amount of gene expression was then calculated as the
difference between the CT of the sample for the target gene and the
mean CT of that sample for the endogenous control.
Human cDNA 28k microarrays
Microglia plated at 1×106 cells/100mmdish were stimulated with
10 μg/ml PIC or 100 ng/ml LPS for 6 h or 16 h in DMEM containing 5%
FCS. Microglia were also infected with 150 ng/ml of VSVg env HIV for
24 h. Cell harvest, RNA isolation, and microarrays (obtained from the
Albert Einstein College of Medicine cDNA Microarray Facility: http://
microarray1k.aecom.yu.edu) were performed as described previously
(Rivieccio et al., 2005, 2006; John et al., 2005). Approximately 5 μg of
total RNA was used for T7 linear ampliﬁcation. Linear ampliﬁcation of
total RNA and subsequent ﬂuorescent labeling of corresponding cDNA
was carried out using the MessageAmp T7 linear ampliﬁcation kit
(Ambion) and cDNA labeling protocols developed at the AECOM
Microarray Facility. Hybridization to cDNA arrays was carried out
overnight at 50 °C in a buffer containing 30% formamide, 3× SSC, 0.75%
SDS and 100 ng of human Cot-1 DNA. Following hybridization, slides
were brieﬂy washed with a solution of 1× SSC, 0.1% SDS, then washed
for 20 min at room temperature in 0.2× SSC, 0.1% SDS and 20 min at
room temperature in 0.1× SSC (without SDS). Independent measure-ments of Cy5 and Cy3 signal intensity and backgroundwere generated
for each cDNA element using a Genepix 4000B scanner (Axon Instru-
ments) and Scanalyze software (http://rana.lbl.gov/EisenSoftware.
htm). The ratio of the ﬂuorescence intensities of the two dyes
represented a measure of differential gene expression between the
individual treatments and their corresponding controls. Cutoff values
were established as Cy5:Cy3 ratio N1.5 or b0.67 and as net signal
intensity more than three times background in one or both channels.
All elements not satisfying both criteria were discarded. Controls
included reversing the ﬂuorochromes and labeling the same sample
using both Cy3 and Cy5.
Statistical analysis
Results shown are representative of two to ﬁve separate expe-
riments using cells from different brain cases. For statistical analysis of
the data within individual experiments, Student's t-test was per-
formed to compare differences between the treatment and control
groups. In addition, a one-way analysis of variance (ANOVA) was
performed to determine whether there were signiﬁcant differences
between conditions.When this analysis indicated signiﬁcance (b0.05),
Tukey post test was performed to determine which conditions were
signiﬁcantly different from each other.Acknowledgments
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